Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 21:360:k872.
doi: 10.1136/bmj.k872.

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study

Devin Abrahami  1   2 , Antonios Douros  1   2   3 , Hui Yin  1 , Oriana Hoi Yun Yu  1   4 , Christel Renoux  1   2   5 , Alain Bitton  6   7 , Laurent Azoulay  1   2   8
Affiliations

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study

Devin Abrahami et al. BMJ. .

Abstract

Objective: To assess whether the use of dipeptidyl peptidase-4 inhibitors is associated with the incidence of inflammatory bowel disease in patients with type 2 diabetes.

Design: Population based cohort study.

Setting: More than 700 general practices contributing data to the United Kingdom Clinical Practice Research Datalink.

Participants: A cohort of 141 170 patients, at least 18 years of age, starting antidiabetic drugs between 1 January 2007 and 31 December 2016, with follow-up until 30 June 2017.

Main outcome measures: Adjusted hazard ratios for incident inflammatory bowel disease associated with use of dipeptidyl peptidase-4 inhibitors overall, by cumulative duration of use, and by time since initiation, estimated using time dependent Cox proportional hazards models. Use of dipeptidyl peptidase-4 inhibitors was modelled as a time varying variable and compared with use of other antidiabetic drugs, with exposures lagged by six months to account for latency and diagnostic delays.

Results: During 552 413 person years of follow-up, 208 incident inflammatory bowel disease events occurred (crude incidence rate of 37.7 (95% confidence interval 32.7 to 43.1) per 100 000 person years). Overall, use of dipeptidyl peptidase-4 inhibitors was associated with an increased risk of inflammatory bowel disease (53.4 v 34.5 per 100 000 person years; hazard ratio 1.75, 95% confidence interval 1.22 to 2.49). Hazard ratios gradually increased with longer durations of use, reaching a peak after three to four years of use (hazard ratio 2.90, 1.31 to 6.41) and decreasing after more than four years of use (1.45, 0.44 to 4.76). A similar pattern was observed with time since starting dipeptidyl peptidase-4 inhibitors. These findings remained consistent in several sensitivity analyses.

Conclusions: In this first population based study, the use of dipeptidyl peptidase-4 inhibitors was associated with an increased risk of inflammatory bowel disease. Although these findings need to be replicated, physicians should be aware of this possible association.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: this study was funded by the Canadian Institutes of Health Research; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
Flowchart of patients included in base and study cohorts
Fig 2
Fig 2
Forest plot summarising results of primary analysis and sensitivity analyses, showing adjusted hazard ratios and 95% CIs for association between use of dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease
See this image and copyright information in PMC

Comment in

References

    1. Christensen DH, Rungby J, Thomsen RW. Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014. Clin Epidemiol 2016;8:381-7. 10.2147/CLEP.S113211 - DOI - PMC - PubMed
    1. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 2009;23:479-86. 10.1016/j.beem.2009.03.004 - DOI - PubMed
    1. Nauck MA, Vilsbøll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009;32(Suppl 2):S223-31. 10.2337/dc09-S315 - DOI - PMC - PubMed
    1. Son JW, Kim S. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies. Diabetes Metab J 2015;39:373-83. 10.4093/dmj.2015.39.5.373 - DOI - PMC - PubMed
    1. Chen X. Biochemical Properties of Recombinant Prolyl Dipeptidases DPP-IV and DPP8. In: Lendeckel U, Reinhold D, Bank U, eds. Dipeptidyl Aminopeptidases: Basic Science and Clinical Applications. Springer US, 2006: 27-32 10.1007/0-387-32824-6_3. - DOI - PubMed

Publication types

Substances

Grants and funding